Navigation Links
A cost effective heart failure drug hits the market!

With sky high health-care costs it has become a burden both on the body as well as the purse if sickness strikes. But as a respite comes a new cardio drug that negates both the above said effects of ill health. //

The drug is in the African-American heart failure patients where it has greatly improved the condition.

Derek Angus, M.D., M.P.H., professor of critical care medicine at the University Of Pittsburgh School Of Medicine led the study where in he examined data from the African-American Heart Failure Trial (A-HeFT) study in order to determine the trial participants' ongoing health care costs. The comparison was made in patients who took a medication with two active drug ingredients, isosorbide dinitrate and hydralazine (ISDN/HYD), to those in patients receiving a placebo regimen. The trial demonstrated the effectiveness of ISDN/HYD for treating heart failure in African-American patients.

The result demonstrated that total health care costs for the AHeFT participants who were treated with ISDN/HYD were 22 percent lower. Health care costs specifically related to heart failure were almost 34 percent lower on average, $5,997 versus $9,144. When the cost of the drug was factored in, there was still an average savings of 6 percent, or $533, on heart failure-related costs for ISDN/HYD patients compared to those who didn't receive the drug, and a 9 percent, or $1,730, average savings on total health care costs.

As stated by Dr. Angus, "This medication clearly decreased healthcare costs for AHeFT participants during the course of the clinical trial, even when the cost of the drug itself was taken into account. Based on the savings we've seen for one year and our modelling that projects future health care cost expenditures, it's likely that the cost-effectiveness of this drug will bear out in the long term as well."

Dr. Angus and his colleagues developed a model to predict costs over the course of the pa tient's lifespan beyond the 12-month trial period. Even under the most pessimistic assumption that, over time, the drug would no longer provide therapeutic benefits the model predicted that for 95 percent of patients, health care costs would still amount to less than what is considered to be a reasonable threshold for cost-effectiveness.

As another statement by Dr.Angus clarifies, "Using very conservative restrictions, our model suggests that this drug, even if used for lifetime courses over many years, should be very cost-effective. The key will be appropriate patient selection and careful attention to compliance with treatment. Our findings apply to the types of individuals, African-Americans with moderate to severe heart failure, who were enrolled in AHeFT. We do not know whether similar benefits would be found in other groups of patients."

"Because we relied on the actual data regarding health care resource use, our primary findings are likely to be very robust, as robust as the overall clinical trial results from AHeFT," said Dr. Angus.

A-HeFT involved 1,050 African-American patients at 11 sites with New York Heart Association Class III or Class IV failure, which is defined as moderate to severe heart failure resulting in significant limitations to physical activity. AHeFT participants were randomly assigned to receive ISDN/HYD or a placebo in addition to their regular heart failure therapy. The patients' age averaged 56.8 years, and 40 percent of the patients were women. The patients were followed for an average of 12.8 months, and the study ended prematurely when a preliminary analysis showed that patients treated with ISDN/HYD had a significantly lower mortality 6.2 percent compared to 10.2 percent.

This study was aimed at the African –American community only.
'"/>




Related medicine news :

1. Morning after pill effective up to five days after having unprotected sex
2. Distraction therapy found very effective in postoperative patients
3. TELITHROMYCIN - the proven effective new drug for cap
4. Digital mammography proves effective
5. Treatment for pre-menstrual syndrome is ineffective
6. Cost-effective antibiotics for sinusitis treatment
7. An effective way to treat angina
8. Fluoride proves effective against fractures
9. Meningitis C vaccine a cost-effective success
10. An effective drug for lung cancer
11. Naltrexone effective for drinking problems
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2017)... ... September 25, 2017 , ... “Renew Refresh Restore Reward”: is a story ... is the creation of published author, Deborah Freeman, cofounded the Free Spirit Bible Church ... returned to our cars, my sister-in-law invited us to come over before the baby ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Majestic Unicorn”: a ... flood. “The Majestic Unicorn” is the creation of published author, Dayna Chantel, an artist ... from far and wide to march aboard the cypress ark-vessel. Male and female, no ...
(Date:9/25/2017)... New York, NY and Los Angeles, CA (PRWEB) , ... September ... ... City, has announced the opening of a full-time office in downtown Los Angeles, to ... Texas, Arizona, Nevada and the surrounding areas. , “We are seeing an ever-increasing amount ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... September 28, 2017 to deliver a powerful message of teamwork, unity and collaboration ... Feature film writer/director Robert Adetuyi (Beat the World, Stomp the Yard) and Grammy-nominated ...
(Date:9/24/2017)... ... September 25, 2017 , ... The Venetian on Grace Bay in ... 1st. And, throughout the month of October, the resort will be offering 40% ... and Maria have passed and damage to the Venetian was very minimal and mostly ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/7/2017)... 2017  Eli Lilly and Company (NYSE: ... operations to more efficiently focus resources on developing ... Global workforce reductions, including those from a U.S. ... approximately 3,500 positions. With the ... of approximately $500 million that will begin to ...
Breaking Medicine Technology: